Moderna, Inc. (NASDAQ:MRNA) revealed topline results on Wednesday from a Phase 3 trial evaluating the efficacy of mRNA-1647, the company’s investigational cytomegalovirus (CMV) vaccine. CMV is a ...

After only 28 days of treatment with ARCT-032 (10 mg), 4 out of 6 Class I CF participants exhibited encouraging reduction of mucus plug number and mucus volume 12-week study enrolling up to 20 CF ...

Chemours is expanding its private well water sampling for PFAS contamination to an additional 14,000 residences in the Wilmington area. The expansion follows a 2019 consent order requiring Chemours to ...

Get your news from a source that’s not owned and controlled by oligarchs. Sign up for the free Mother Jones Daily. As part of the Affordable Care Act, which paved the way for more widespread access to ...

Zohran Mamdani's New York City mayoral opponents ridiculed his plan to phase out the city's gifted program for public school kindergartners. Mamdani, the New York City Democratic mayoral nominee, ...

Mayoral front-runner Zohran Mamdani wants to phase out New York City’s Gifted and Talented program — the democratic socialist’s latest move to revert to ex-Mayor Bill de Blasio’s era. Mamdani, the ...

NEW YORK — Zohran Mamdani, the Democratic front-runner for mayor of New York City, plans to end the gifted and talented program for kindergarten students at public schools if he is elected, calling ...

Venu Holding Corporation ("VENU") (NYSE American: VENU), a developer, owner, and operator of upscale live music venues and premium hospitality destinations, has announced the addition of Tommy Ginoza ...

Zohran Mamdani, the Democratic front-runner in the mayor’s race, plans if elected to replace the selective program, which became a symbol of segregation in public schools. By Emma G. Fitzsimmons and ...

A new mural inside the Jeremiah Program’s Brooklyn office is turning heads and hearts in Boerum Hill. Unveiled on Sept. 18, the vibrant piece of public art celebrates the resilience, strength and ...

Genfit has stopped development of VS-01 in acute-on-chronic liver failure (ACLF) after a patient suffered a serious adverse event in a phase 2 trial. The French drugmaker acquired VS-01 when it bought ...